ГЕРК Филлип М. (US),БАРР Уилльям Х. (US),РИТТЕР Джозеф К. (US)
申请号：
RU2014116639/15
公开号：
RU2014116639A
申请日:
2012.09.27
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of oral delivery of a biologically active substance to an individual in need thereof in order to increase the bioavailability of a given biologically active substance, comprising the step of an oral administration of a given biologically active substance by an individual in combination with one or more inhibitors of one or more sulfotransferases (SULT). 2. The method of claim 1, further comprising administering to said individual one or more monoamine oxidase inhibitors (MAOs). The method of claim 1, further comprising administering to said individual one or more uridine diphosphate glucuronosyl transferase (UGT) inhibitors. The method according to claim 1, characterized in that the biologically active substance is phenylephrine. The method according to claim 2, characterized in that the biologically active substance is phenylephrine. A method according to claim 3, characterized in that the substance is phenylephrine. The method of claim 1, wherein said one or more SULT inhibitors inhibit SULT 1A3.8. A method for oral delivery of phenylephrine to an individual in need thereof, which increases the bioavailability of phenylephrine, comprising the step of orally administering phenylephrine to said individual in combination with one or more phenols or alkylated catechols. A method according to claim 8, characterized in that said phenols or alkylated catechols are selected from guaiacol, isoeugenol, zingeron, vanillin, ethyl vanillin, curcumin and piperine. A method according to claim 9, characterized in that said administration step comprises oral administration of one or more phenolic compounds, which are not alkylated catechols. The method of claim 10, wherein1. Способ пероральной доставки биологически активного вещества индивидууму, нуждающемуся в этом, чтобы повысить биодоступность данного биологически активного вещества, включающий этап перорального приема индивидуумом данного биологически активного вещества в комбинации с одним или более ингибиторами о
